FGF21 Analogs of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents

Fibroblast growth factor 21 (FGF21) mitigates many of the pathogenic features of type 2 diabetes, despite a short circulating half-life. PEGylation is a proven approach to prolonging the duration of action while enhancing biophysical solubility and stability. However, in the absence of a specific pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, James, Pinkstaff, Jason, Li, Zhihua, Skidmore, Lillian, Li, Nina, Myler, Heather, Dallas-Yang, Qing, Putnam, Anna-Maria, Yao, Jun, Bussell, Stuart, Wu, Margaret, Norman, Thea C., Rodriguez, Carlos G., Kimmel, Bruce, Metzger, Joseph M., Manibusan, Anthony, Lee, Darin, Zaller, Dennis M., Zhang, Bei B., DiMarchi, Richard D., Berger, Joel P., Axelrod, Douglas W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2012
Materias:
Pharmacology and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266413/
https://www.ncbi.nlm.nih.gov/pubmed/22210323
http://dx.doi.org/10.2337/db11-0838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266413/
https://www.ncbi.nlm.nih.gov/pubmed/22210323
http://dx.doi.org/10.2337/db11-0838

Ejemplares similares